Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The Trump administration has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway the White House can actually make with these reforms, even after the House of Representatives vote on Trump’s repeal of Obamacare.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
Short interest in Pfizer Inc. (NYSE: PFE) fell to 47.33 million shares from the previous 50.04 million. Its shares were last seen at $33.38, within a 52-week trading range of $29.83 to $37.39.
The number of Merck & Co. Inc. (NYSE: MRK) shares short fell to 15.07 million from 16.67 million in the previous period. Its shares were trading at $63.29, in a 52-week range of $53.59 to $66.80.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest rose to 22.63 million shares, compared to the previous level of 21.80 million. Shares were trading at $31.15, in a 52-week range of $30.22 to $56.46.
Bristol-Myers Squibb Co. (NYSE: BMY) short interest dropped to 18.41 million shares, from the previous reading of 22.34 million. Shares were trading at $55.32, within a 52-week range of $46.01 to $77.12.
The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 32.65 million, compared to the previous 33.32 million. The stock was trading at $66.17, in a 52-week range of $55.06 to $68.12.
Eli Lilly and Co.’s (NYSE: LLY) short interest decreased slightly to 10.76 million shares from the previous 10.80 million. The stock was trading at $80.79. The 52-week range is $64.18 to $86.72.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
